Truist Financial Corp Genmab A/S Transaction History

Truist Financial Corp

$71.8 Billion
Q3 2025

A detailed history of Truist Financial Corp transactions in Genmab A/S stock. As of the latest transaction made, Truist Financial Corp holds 26,717 shares of GMAB stock, worth $808,456. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,717

Previous 26,526 0.72%

Holding current value

$808,456

Previous $548,000 49.45%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 03, 2025	BUY	$20.3 - $30.67 $3,877 - $5,857	191 Added 0.72%	26,717 $819,000
Q2 2025 Jul 18, 2025	SELL	$17.98 - $23.09 $44,284 - $56,870	-2,463 Reduced 8.5%	26,526 $548,000
Q1 2025 Apr 29, 2025	BUY	$18.69 - $24.14 $26,764 - $34,568	1,432 Added 5.2%	28,989 $567,000
Q4 2024 Jan 31, 2025	SELL	$20.02 - $24.15 $352,732 - $425,498	-17,619 Reduced 39.0%	27,557 $575,000
Q3 2024 Nov 13, 2024	SELL	$23.84 - $28.48 $464,403 - $554,790	-19,480 Reduced 30.13%	45,176 $1.1 Million

Q2 2024 Aug 20, 2024	BUY	$25.13 - $30.27 $50 - $60	2 Added 0.0%	64,656 $1.62 Million
Q1 2024 May 10, 2024	BUY	$26.43 - $32.77 $213,607 - $264,847	8,082 Added 14.29%	64,654 $1.93 Million
Q4 2023 Feb 02, 2024	SELL	$27.94 - $35.44 $162,191 - $205,729	-5,805 Reduced 9.31%	56,572 $1.8 Million
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $1.71 Million - $2.05 Million	48,623 Added 353.52%	62,377 $2.2 Million
Q2 2023 Aug 01, 2023	SELL	$37.4 - $42.94 $2,281 - $2,619	-61 Reduced 0.44%	13,754 $522,000
Q1 2023 May 05, 2023	SELL	$34.88 - $43.22 $238,369 - $295,365	-6,834 Reduced 33.1%	13,815 $521,000
Q4 2022 Feb 17, 2023	BUY	$33.8 - $47.06 $2,399 - $3,341	71 Added 0.35%	20,649 $875,000
Q3 2022 Oct 26, 2022	BUY	$31.52 - $373.61 $175,503 - $2.08 Million	5,568 Added 37.1%	20,578 $662,000
Q2 2022 Jul 22, 2022	SELL	$26.83 - $38.57 $37,776 - $54,306	-1,408 Reduced 8.58%	15,010 $488,000
Q1 2022 Apr 22, 2022	SELL	$30.95 - $39.68 $83,348 - $106,858	-2,693 Reduced 14.09%	16,418 $594,000
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $71,847 - $94,381	-2,003 Reduced 9.49%	19,111 $756,000
Q3 2021 Nov 05, 2021	BUY	$41.55 - $48.72 $222,334 - $260,700	5,351 Added 33.95%	21,114 $923,000
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $75,426 - $102,243	-2,294 Reduced 12.7%	15,763 $644,000
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $54,728 - $78,588	1,770 Added 10.87%	18,057 $593,000
Q4 2020 Feb 18, 2021	BUY	$33.66 - $40.76 $14,305 - $17,323	425 Added 2.68%	16,287 $662,000
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $73,845 - $86,372	-2,233 Reduced 12.34%	15,862 $580,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $93,974 - $158,842	4,687 Added 34.96%	18,095 $613,000
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $47,711 - $70,162	2,782 Added 26.18%	13,408 $284,000
Q4 2019 Feb 14, 2020	BUY	$18.88 - $24.14 $200,618 - $256,511	10,626 New	10,626 $237,000

Others Institutions Holding GMAB

# of Institutions

276

Shares Held

62.7M

Call Options Held

58.8K

Put Options Held

10.2K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $19.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.

Account

Truist Financial Corp Genmab A/S Transaction History